Dat Ngo

Dat Ngo

Auto-generated profile, based on publicly available information

Dat Ngo

Department of Pharmacy, City of Hope National Medical Center, Duarte, CA, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2025 in Blood Advances
Verified
Journal Article
Open access
Ibrahim AldossIbrahim Aldoss
Ibrahim Aldoss
SLShanpeng Li
Shanpeng Li
JZJianying Zhang
Jianying Zhang
MCMary C. Clark
Mary C. Clark
VAVaibhav Agrawal
Vaibhav Agrawal
VPVinod Pullarkat
Vinod Pullarkat
Despite the success of the CD19 × CD3 T-cell engager blinatumomab in B-cell acute lymphoblastic leukemia (B-ALL), treatment failure is common and can manifest with antigen loss and extramedullary disease (EMD) relapse. To understand the impact of leukemia genetics on outcomes, we reviewed 267 adult patients with B-ALL treated with blinatumomab and used next-generation sequencing to identify molecular alterations. Patients received blinatumomab for relapsed/refractory (R/R) disease (n = 150) and minimal residual disease (MRD; n = 88), upfront as induction (n = 10) or as consolidation in MRD-negative state (n = 19). In the overall cohort, 50 patients (19%) had Philadelphia chromosome (Ph)–positive ALL, 80 (30%) had Ph-like ALL, 35 (13%) had TP53 mutations (TP53m), 7 (3%) had KMT2A rearrangement, and 8 (3%) had PAX5 alterations. For patients treated for R/R ALL, the overall complete remission (CR)/CR with incomplete hematological recovery (CRi) rate was 59%. Only pretreatment high disease burden (P < .01) and active EMD (P < .01) were associated with inferior CR/CRi rate. Of 169 patients in CR/CRi after blinatumomab, 79 (47%) patients relapsed, including 22 (28%) with CD19– and 54 (68%) with CD19+ relapse. In multivariable analysis, TP53m was associated with an increased risk of CD19– relapse (hazard ratio [HR], 6.84; 95% confidence interval [CI], 2.68-17.45; P < .01). Post-blinatumomab allogeneic stem cell transplantation consolidation was associated with a lower risk of CD19– relapse (HR, 0.10; 95% CI, 0.03-0.37; P < .01) and EMD relapse (HR, 0.36; 95% CI, 0.18-0.73; P < .01). In conclusion, leukemia genetics may predict patterns of blinatumomab failure, with TP53m associated with CD19– relapse.

29 May 2024 in British Journal of Haematology
Verified
Journal Article
Closed access
TOTamer Othman
Tamer Othman
PKPaul Koller
Paul Koller
HPHoda Pourhassan
Hoda Pourhassan
VAVaibhav Agrawal
Vaibhav Agrawal
DNDat Ngo
Dat Ngo
Ibrahim AldossIbrahim Aldoss
Ibrahim Aldoss

1 September 2025 in British Journal of Haematology
Verified
Journal Article
Closed access
HPHoda Pourhassan
Hoda Pourhassan
JTJose Tinajero
Jose Tinajero
HMHuiyan Ma
Huiyan Ma
RJRyan Jackson
Ryan Jackson
RPRaju Pillai
Raju Pillai
Ibrahim AldossIbrahim Aldoss
Ibrahim Aldoss

6 November 2024 in British Journal of Haematology
Verified
Journal Article
Closed access
JTJose Tinajero
Jose Tinajero
SXSharon Xu
Sharon Xu
DNDat Ngo
Dat Ngo
SLShanpeng Li
Shanpeng Li
JPJoycelynne Palmer
Joycelynne Palmer
Ibrahim AldossIbrahim Aldoss
Ibrahim Aldoss

4 May 2025 in Expert Opinion on Investigational Drugs
Verified
Journal Article
Closed access
DNDat Ngo
Dat Ngo
JTJose Tinajero
Jose Tinajero
SOSalman Otoukesh
Salman Otoukesh
KSKaramjeet Sandhu
Karamjeet Sandhu
HAHaris Ali
Haris Ali
ASAmandeep Salhotra
Amandeep Salhotra
Chronic graft-versus-host disease (cGVHD) is the most common cause of late non-relapse mortality after allogeneic hematopoietic cell transplantation (allo-HCT). Rho-associated coiled-coiled kinases (ROCK) inhibitors have shown to balance the pro-inflammatory and regulatory T-cell subsets in addition to reducing fibrosis in cGVHD, resulting in the development of multiple ROCK2 inhibitors including belumosudil. We describe the pathophysiology of cGVHD and the role of ROCK2 in cGVHD. This includes a review of the current and ongoing clinical data with belumosudil, and an overview of current ROCK2 inhibitors in development for cGVHD including rovadicitinib, zelasudil and GV-101. Many of the recent novel agents with unique mechanisms such as ROCK2 inhibitors (i.e. belumosudil) provide high response rates but rarely yield complete responses in cGVHD. The future of management of cGVHD will rely on investigating combination therapy upfront that may achieve deeper complete responses, developing newer preventative therapies, and advancements in biomarker detection/risk stratification for cGVHD.

21 June 2022 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
DNDat Ngo
Dat Ngo
SOSalman Otoukesh
Salman Otoukesh
ASAnthony S. Stein
Anthony S. Stein
SFStephen Forman
Stephen Forman
VPVinod Pullarkat
Vinod Pullarkat
Ibrahim AldossIbrahim Aldoss
Ibrahim Aldoss
Blinatumomab is a CD3/CD19 bispecific T-cell engager that has established clinical activity in patients with acute lymphoblastic leukemia (ALL) with either relapsed/refractory (R/R) or detectable m...